Abstract:Proteolysis targeting chimera (PROTAC) technology, a groundbreaking strategy for degradation of pathogenic proteins by hijacking of the ubiquitin-proteasome-system has become a promising strategy in drug design. However, the real-time monitoring and visualization of protein degradation processes have been long-standing challenges in the realm of drug development. In this research, we sought to amalgamate the highly efficient protein-degrading capabilities of PROTAC technology with the visualization attributes of fluorescent probes, with the potential to pave the path for the design and development of a novel class of visual PROTACs. These novel PROTACs uniquely possess both fluorescence imaging and therapeutic characteristics, all with the goal of enabling real-time observations of protein degradation processes. Our approach involved the utilization of a high ER-targeting fluorescent probe, previously reported in our laboratory, which served as a warhead that specifically binds to the protein of interest (POI). Additionally, a VHL ligand for recruiting E3 ligase and linkers of various lengths were incorporated to synthesize a series of novel ER-inherent fluorescence PROTACs. Among them, compound A3 demonstrated remarkable efficiency in degrading ERα proteins (DC 50 = 0.12 μM) and displaying exceptional anti-proliferative activity against MCF-7 cells (IC 50 = 0.051 μM). Furthermore, it exhibited impressive fluorescence imaging performance, boasting an emission wavelength of up to 582 nm, a Stokes shift of 116 nm, and consistent optical properties. These attributes make it especially suitable for the real-time, in situ tracking of ERα protein degradation processes, thus may serve as a privileged visual theranostic PROTAC for ERα + breast cancer. This study not only broadens the application spectrum of PROTAC technology but also introduces a novel approach for real-time visualization of protein degradation processes, ultimately enhancing the diagnostic and treatment efficacy of PROTACs.

Discovery of novel protein degraders based on bioorthogonal reaction-driven intracellular self-assembly strategy

Discovery of intracellular self-assembly protein degraders driven by tumor-specific activatable bioorthogonal reaction

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

A modular PROTAC design for target destruction using a degradation signal based on a single amino acid

Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins

Discovery of Alkenyl Oxindole as a Novel PROTAC Moiety for Targeted Protein Degradation via CRL4 Recruitment

Discovery of E3 Ligase Ligands for Target Protein Degradation

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

A Practical “Pretacs-Cytoblot” Platform Accelerates the Streamlined Development of PROTAC-based Protein Degraders

The Present and Future of Novel Protein Degradation Technology

Precise Modulation of Protein Degradation by Smart PROTACs

Delivering on Cell‐Selective Protein Degradation Using Chemically Tailored PROTACs

PROTACs: A Novel Strategy for Cancer Drug Discovery and Development

Making Protein Degradation Visible: Discovery of Theranostic PROTACs for Detecting and Degrading NAMPT

Bifunctional Peptide Nanofibrils for Targeted Protein Degradation.

Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation

Fluorescence theranostic PROTACs for real-time visualization of ERα degradation

Recent advances in targeted protein degraders as potential therapeutic agents

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy